NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to demonstrate superiority in progression-free survival
(PFS) when NGR-hTNF is added to standard chemotherapy regimen (cisplatin/gemcitabine or
cisplatin/pemetrexed) in locally advanced (stage IIIb with supraclavicular lymph node
metastases or malignant pleural or pericardial effusion), metastatic (stage IV) or recurrent
non-small cell lung cancer (NSCLC).